Process Optimisation, Pharmaceutical Characterisation, and in vitro Activity of Mesalamine Nanocrystals in PMA-differentiated THP-1 cell Lines in the Late Inflammatory and Profibrotic Phase | Synapse
March 3, 2026
Process Optimisation, Pharmaceutical Characterisation, and in vitro Activity of Mesalamine Nanocrystals in PMA-differentiated THP-1 cell Lines in the Late Inflammatory and Profibrotic Phase
Key Points
Improvement in anti-inflammatory activity indicates the effectiveness of mesalamine nanocrystals in late inflammatory phases.
Key evidence shows a twofold increase in activity compared to conventional mesalamine formulations under similar conditions.
Assessment using in vitro activity benchmarks in PMA-differentiated THP-1 cell lines highlights significant pharmaceutical characterization efforts.
This approach may enable improved drug delivery, but results remain limited to in vitro models with more testing required for in vivo validation.